At the molecular level, the evidence of SF3B1 mutations, either in the presence or absence of activating JAK2 mutations, determines the diagnosis of MDS/MPN-T SF3B1, regardless of the identification of ring sideroblasts, if SF3B1 is detectable with VAF > 10%. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.